FDA Removes from Market Unapproved Cough and Cold Prescription Products - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Removes from Market Unapproved Cough and Cold Prescription Products


ePT--the Electronic Newsletter of Pharmaceutical Technology

FDA announced on Mar. 2, 2011, that it is taking action against companies that manufacture, distribute, or market certain unapproved prescription oral cough, cold, and allergy products, according to an agency release and press briefing.

FDA’s Office of Compliance Director Deborah M. Author explained in a press briefing that the legal requirements for evaluating and approving prescription drugs have changed over the past century, including the enactment of the Food, Drug, & Cosmetic Act, and that, still, many drugs have remained on or entered the market illegally.

This class of drugs is of particular concern because many of these products are labeled as “timed release,” which are complicated to manufacture. It is important, said Author, that FDA review these types of drugs to ensure that the release of the active ingredient is occurring at the right time and in the right dosage. This class of drugs is also important because many of the products are labeled for children age 2 and under. In 2008, the agency called for the relabeling of over-the-counter cough, cold, and allergy medications for children under age 2 because of potential serious side effects.

According to the agency press release, “Unapproved prescription cough, cold, and allergy drug products have not been evaluated by the FDA for safety, effectiveness, and quality. People may be at greater risk when using these products than when using FDA-approved prescription drugs or drugs that are appropriately marketed over-the-counter.” 

The action, which is part of FDA’s 2006 unapproved drugs initiative, calls for companies that have previously listed products subject to FDA’s action to stop manufacturing the products within 90 days and to stop shipping the products within 180 days.  In addition, companies that have not previously listed products subject to today’s action with FDA are asked to stop manufacturing and shipping their products immediately. The overall initiative has prompted the removal of 550 unapproved products from the market in the past five years. This latest action affects 500 unapproved prescription products.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here